cannabis rescheduling moved to center stage this week after the U.S. Department of Justice filed a brief in the U.S. Court of Appeals for the District of Columbia Circuit that prompted a public rebuke from MMJ International Holdings, Inc. The company said the filing signals a legal approach that could weaken federal standards for drug approvals and workplace drug testing.
On July 3, 2026, MMJ International and its subsidiaries — MMJ BioPharma Cultivation, Inc. and MMJ BioPharma Labs, Inc. — issued a statement criticizing the DOJ filing. MMJ said the government’s argument effectively tells the court “that protecting patients through the FDA approval process and protecting the public through workplace drug testing are not interests the Controlled Substances Act was designed to protect.” Duane Boise, MMJ CEO, added, “We respectfully disagree. Congress enacted the CSA to protect public health, scientific integrity, and public safety—not to reward those who bypassed the federal system while penalizing those who followed it.”
MMJ noted its own role in clinical research, citing ongoing cannabinoid studies for Huntington’s disease and multiple sclerosis. The company frames the DOJ filing as a practical threat to companies that invested in federal-compliant research and product development: if courts accept the DOJ’s legal position, MMJ warns, firms that followed FDA pathways and federal registration could face competitive or legal disadvantages compared with entities that operated outside those procedures.
The filing sits within a broader regulatory dispute over how federal law treats cannabis. The Controlled Substances Act (CSA) classifies substances by schedule based on accepted medical use and risk of abuse; any court interpretation that deprioritizes FDA approval or workplace safety concerns could change how courts apply the CSA in future challenges. MMJ’s filing-response highlights three concrete areas of concern:
– FDA approval process: MMJ argues that the DOJ brief diminishes the role of FDA review. Companies that fund clinical trials and pursue FDA authorization say they incur substantial costs and regulatory requirements. MMJ frames the DOJ position as a disincentive to follow those procedures.
– Workplace drug testing: MMJ warns that the DOJ’s stance could limit courts’ willingness to consider workplace safety and testing protocols as valid CSA-related interests. That shift could affect employers that rely on federal or state testing programs to maintain safety-sensitive operations.
– Clinical research continuity: MMJ pointed to its own clinical work on Huntington’s disease and multiple sclerosis as at-risk activities. The company says a legal standard that downplays scientific review could reduce investor confidence and slow trial enrollment for federally aligned studies.
MMJ’s public reaction follows a pattern of industry groups and medical-research firms pressing courts and regulators to treat federally-compliant cannabis activities as legitimate business and research operations. MMJ framed the DOJ filing as turning compliance into a liability: “compliance with federal standards has become a liability rather than a hallmark of legitimacy,” the company said.
The DOJ filing itself is part of ongoing litigation over federal handling of cannabis scheduling and related policy disputes; the filing’s exact legal arguments were not reproduced in MMJ’s statement. The U.S. Court of Appeals for the D.C. Circuit will consider briefs and legal positions before any ruling that could affect nationwide precedents.
Industry stakeholders are watching for several measurable outcomes that could result from a court decision consistent with the DOJ brief: changes in how courts weigh FDA approval in CSA cases; modifications to employer testing requirements tied to federal law; and shifts in investment patterns for companies that spend millions on compliant cultivation, lab work and clinical trials. MMJ’s statement implies that the company views its research pipeline and regulatory compliance as long-term financial commitments at risk from changing legal interpretations.
Separately, MMJ’s release was distributed via ACCESS Newswire and carries the company’s call for courts to uphold federal processes that govern drug testing and drug approvals. The company said it will continue to press its position in court and through public statements.
What happens next: the D.C. Circuit will set briefing dates and, eventually, a decision timetable. Any opinion that narrows the relevance of FDA approval or workplace safety to CSA questions could be cited in future appeals and district-court cases. For clinical researchers and regulated businesses, the ruling could alter the legal incentives for pursuing federal pathways versus state-only markets.
MMJ’s filing and the DOJ brief illustrate a specific legal tension: whether adherence to federal regulatory pathways should influence judicial outcomes under the CSA. The forthcoming appellate decisions will provide the first concrete signals about how courts will balance those factors in the near term.
